- cafead Sep 07, 2021 at 11:02: PM
via The U.S. Court of Appeals for the Federal Circuit has upheld a prior win for the companies covering two Eliquis patents—the drug’s composition of matter patent and a formulation patent. While the case is subject to another potential appeal, this appeals win sets the companies up to retain U.S. exclusivity until April 1, 2028.
article source
article source